Individual Patient Expanded Access IND of Autologous HBadMSCs for the Treatment of Amyotrophic Lateral Sclerosis

NO_LONGER_AVAILABLE

Conditions studied: Amyotrophic Lateral Sclerosis

In brief

The drug for this submission is Hope Biosciences' autologous, adipose-derived culture-expanded mesenchymal stem cells (HB-adMSCs) for the treatment of a single patient with Amyotrophic Lateral Sclerosis (ALS). Stem cells have become a promising tool for the treatment of inflammatory and neurodegenerative conditions, including autoimmune diseases, traumatic brain injury, Parkinson's disease, and Alzheimer's disease.

Key facts

Study ID

NCT04514952

Run by

Hope Biosciences Research Foundation

Last updated by the study team

2025-09-29

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Documented diagnosis of Amyotrophic Lateral Sclerosis.
• Capable of giving informed consent (signed, verbal or assent as applicable and as listed in the protocol)

You may not qualify if…

• Other acute or chronic medical conditions that, in the opinion of the investigator, may increase the risks associated with study participation or HB-adMSCs administration.
• Any abnormal, inexplicable laboratory result that, in the opinion of the investigator, may increase the risks associated with study participation or HB-adMSCs administration.
• Participation in other interventional research studies within the past 30 days.
• Unwillingness to return for follow-up visits.

Where it is running

• River Oaks Hospital and Clinics — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.